ImmuneCare

ImmuneCare Biopharmaceuticals (Shanghai) Co., Ltd. is a clinical-stage biotechnology company and a subsidiary of ImmuneOnco Biopharmaceuticals. The company focuses on developing innovative immunotherapies for non-oncology indications, particularly in the fields of autoimmune diseases, rare diseases, and metabolic disorders. Its lead programs include amulirafusp alfa (IMC-002), a CD47xCD20 bispecific antibody being evaluated for Neuromyelitis Optica Spectrum Disorder (NMOSD) and Systemic Lupus Erythematosus (SLE), and IMC-003, an ActRIIA-Fc fusion protein in development for Pulmonary Arterial Hypertension (PAH). Leveraging the proprietary R&D platforms of its parent company, ImmuneCare aims to address significant unmet medical needs through targeted biologics and novel mechanisms of action.